|
Fish
|
Cumulative mortality
|
Mean Cumulative Mortality
|
Mean day to death ± SE
|
HR (95%CI)
|
RPS
|
P-value
|
---|
MUS-1
|
pVHSivb-G
|
10
|
0%
|
5%
|
NA
|
0.016 (0.002–0.124)
|
95%
|
0.003
|
pVHSivb-G
|
10
|
10%
|
pcDNA
|
10
|
100%
|
100%
|
11.7 ± 1.3
| |
NA
|
NA
|
pcDNA
|
10
|
100%
|
MUS-2
|
pVHSivb-G
|
10
|
30%
|
15%
|
10.6 ± 0.4
|
0.063 (0.018–0.223)
|
85%
|
0.030
|
pVHSivb-G
|
10
|
0%
|
pcDNA
|
10
|
100%
|
100%
|
9.9 ± 1.0
| |
NA
|
NA
|
pcDNA
|
10
|
100%
|
MUS-3
|
pVHSivb-G
|
10
|
0%
|
0%
|
NA
|
NA
|
100%
|
<0.0001
|
pVHSivb-G
|
10
|
0%
|
pcDNA
|
10
|
100%
|
100%
|
12.8 ± 1.8
| |
NA
|
NA
|
- Total number of fish challenged in each trial, mean cumulative % mortality, and mean days to death of each treatment. The table also includes mean day to death calculated using PROC LIFETEST in SAS [22]. A Cox proportional hazard model was also fitted using SAS to examine the hazard ratio (HR) between glycoprotein (G) gene and mock-vaccinated counterparts. The relative percent survival (RPS) was calculated between treatments as previously described [23]. The P-values are from t-tests testing survival differences between the treatments that were conducted using PROC TTEST in SAS